Currently Viewing:
Newsroom

China on the Cusp of Anticancer Biosimilar Wave, Report Says

Tony Hagen
China’s biosimilar development engine is supercharged and running on octane, a recent report said.
China has lagged in the adoption of anticancer biosimilars, but a huge number of agents in development suggest an “incoming wave” of these agents is about to hit, according to authors of a recent study.

Just 2 anticancer biosimilars were approved in China by the end of 2019, but the country has 23.9% of the global cancer burden. The turning point in China could occur very soon, the authors said, noting that 54 anticancer biosimilars representing 7 reference products are under clinical development in mainland China, 3 are involved in new drug application reviews, and 27 are in late-phase efficacy comparative studies.

These findings were included in a report of biosimilar adoption in 40 countries with 78.1% of the worldwide cancer incidence. China’s biosimilar development engine is supercharged and running on octane, the report said.

Visit The Center for Biosimilars for the full story

 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up